Forbes May 5, 2020
The ability to accelerate drug discovery is necessary. I recently spoke with Jeffrey Reid, Head of Genomics and Data Engineering for Regeneron. Reid works in the Regeneron Genetics Center (RGC), a research initiative that seeks to improve patient care by using genomic approaches to speed drug discovery and development. The genetics center is a unit of Regeneron (NASDAQ: REGN), a leading biotechnology company that has been at the forefront of drug discovery for 3 decades. The firm’s focus on translating science into medicine has led to seven FDA-approved treatments. The Regeneron Genetics Center is engaged in one of the largest genetics sequencing efforts in the world.
Reid describes his role as existing at the intersection of science and data, noting...
Today's Sponsors
Today's Sponsor